Sales & Support: +44 (0)1223 316 855

COVID-19 diagnostic assays

In support of COVID-19 testing, research and vaccine development, Cambridge Bioscience have partnered with Beijing Wantai Biological Pharmacy to supply a series of innovative, highly sensitive and specific CE-marked serological assays. Together, the Wantai tests offer a total testing solution for COVID-19 diagnosis with results in 75-minutes. These assays have been extensively evaluated across Europe and are being used widely.

Kit evaluation
The Wantai SARS-CoV-2 total antibody ELISA was recently evaluated and compared to 7 other commercial COVID-19 serology assays in a recent Nature communication:
‘The Wantai ELISA, detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies.’
GeurtsvanKessel, C.H., Okba, N.M.A., Igloi, Z. et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun 11, 3436 (2020)

Assays available
SARS-CoV-2 total antibody ELISA
For the detection of total antibodies (IgG, IgM and IgA) against the S1-RBD of SARS-CoV-2
SARS-CoV-2 total antibody rapid test
A 15-minute test that detects total antibodies against the S1-RBD of SARS-CoV-2
For the detection of lgM-class antibodies to the SARS-CoV-2 virus